Ozempic / GLP-1 Lawsuit Update

What the Ozempic / GLP-1 lawsuit is about

Ozempic and other GLP-1 lawsuits allege inadequate warnings about serious gastrointestinal injuries. MDL-3094 coordinates those federal cases before Judge Karen Spencer Marston in Pennsylvania. Defendants dispute the allegations. NAION vision-loss claims proceed separately in MDL-3163.

Ozempic lawsuit update 2026: November status

MDL-3094 has 4,082 pending actions; the next scheduled status conference is November 17. The November 2, 2026 JPML report lists 4,082 pending actions, up from 4,025 on October 1. Its 4,196 historical actions include cases no longer pending and are not a settlement-participant count.

The public MDL orders list, reviewed November 10, 2026, does not post a later Rule 702 ruling, bellwether trial setting or settlement program. An October 8 order scheduled closing arguments on expert-evidence motions for October 13; that past scheduled date does not establish a trial or a ruling.

The amended conference order schedules status conferences on November 17 and December 15, 2026, at 1 p.m. in Courtroom 16B, Philadelphia. The October 8 order leaves those settings unchanged. A status conference and a Rule 702 hearing are not bellwether trials.

NAION vision-loss claims are coordinated separately in MDL-3163, with 278 pending actions as of November 2. Public court indexes are not complete live PACER dockets; this status reflects the identified records reviewed November 10.

Which drugs are included?

Filed cases involve GLP-1 receptor agonists from two manufacturers:

• Novo Nordisk: Ozempic and Rybelsus (semaglutide for type 2 diabetes), Wegovy (semaglutide for weight management), and Saxenda (liraglutide).
• Eli Lilly: Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide).

Both diabetes patients and weight-loss patients appear among filed cases. The medication involved, dose, duration of use, and documented injury all factor into claim review.

Who may qualify for the Ozempic lawsuit?

There is no automatic qualification rule. Claim review commonly considers:

• Documented use of a GLP-1 medication, supported by prescription and pharmacy records.
• A diagnosis such as gastroparesis, ileus, intestinal pseudo-obstruction, or bowel obstruction — often supported by a gastric emptying study, endoscopy, imaging, or hospitalization records.
• Injury timing relative to medication use, and whether other causes were ruled out or disputed.
• State filing deadlines and individual procedural facts.

Severe, medically documented injuries — particularly those involving hospitalization — have been the focus of filed cases.

What evidence can support an Ozempic lawsuit review?

A useful review usually starts with records that identify the GLP-1 medication, show when and how long it was used, document the diagnosed injury, and establish the timing between use, symptoms, and treatment. The evidence needed depends on the alleged injury and individual medical history; possessing a particular record does not guarantee that a claim qualifies.

• Medication proof: prescription records, pharmacy fills, product name, dose changes, and dates of use.
• Diagnosis proof: gastroenterology records, discharge summaries, and records identifying gastroparesis, ileus, bowel obstruction, or another alleged injury.
• Testing and treatment: gastric-emptying studies, imaging, endoscopy, emergency care, hospitalization, surgery, and follow-up treatment when relevant.
• Timeline: dates of medication use, first symptoms, diagnosis, treatment, and any decision to stop or change medication under medical supervision.
• Other medical context: records concerning alternative explanations, prior gastrointestinal history, and other medications may also matter.

The federal proceeding's current schedule and orders are available from the Eastern District of Pennsylvania's MDL-3094 page. Court coordination does not create a universal qualification checklist, and state filing deadlines still require individual review.

Verified litigation updates

The November 2, 2026 JPML report lists 4,082 pending and 4,196 historical actions in MDL-3094, and 278 pending actions in separate MDL-3163. Earlier dated entries follow.

• JPML reports 4,025 pending actions on October 1, 2026, compared with 4,022 on September 1; 4,139 total historical actions are reported separately. Source
• An October 8 scheduling order sets closing arguments on the pending Rule 702 motions for Cross Cutting Issues 2 and 3 for October 13, 2026. No ruling appears on the public orders page reviewed November 10. Source
• The separate NAION vision-loss MDL-3163 has 247 pending actions as of October 1, 2026, compared with 216 on September 1. Source
• The public MDL orders checked November 10 contain no announced bellwether trial date or settlement program. Source

Who may be affected

People who used a GLP-1 medication and then experienced severe, documented gastrointestinal injury — especially gastroparesis confirmed by a gastric emptying study, or a bowel obstruction or ileus requiring emergency care — are the focus of current filings. Family members may have wrongful-death-related questions where an injury contributed to a death; those claims involve additional state-specific rules.

Ozempic hearings and bellwether trials

The August 28 scheduling order set the Rule 702 evidentiary hearing for September 14–18, 2026, and that hearing has been held. An October 8 order scheduled closing arguments on the Rule 702 motions for October 13, 2026. The proceeding concerns expert admissibility and is not a bellwether jury trial; the public MDL orders page reviewed November 10 does not announce a ruling or trial date.

The next scheduled status conference is November 17, 2026 under the amended conference order. A conference date is not a trial date or a promised settlement date.

Injuries alleged in filed cases

Gastroparesis — delayed gastric emptying that can cause persistent vomiting, malnutrition, and long-term complications. Ileus and bowel obstruction — intestinal blockage or paralysis that can require hospitalization or surgery. NAION — a sudden optic-nerve injury associated in some studies with semaglutide use, capable of causing permanent vision loss; NAION claims are consolidated in their own proceeding, MDL-3163 (247 pending actions as of October 1, 2026). Filed complaints also describe severe dehydration, aspiration events, and related complications.

Deadline considerations

GLP-1 claims follow state statutes of limitations, which commonly run two to three years from injury or discovery, depending on the state. Because GLP-1 injuries often develop during ongoing medication use, accrual and discovery-rule questions can be fact-intensive. State-specific pages below outline each state's general framework.

Sources and status notes

Counts use the November 2 JPML report and September 1 report. Court assignments and transfer dates use the JPML by-number report. Status was checked November 10, 2026 against public court records; these public indexes are not complete live dockets.

• October 8, 2026 scheduling order setting Rule 702 closing arguments for October 13.
• The separate NAION vision-loss MDL-3163 has 247 pending actions as of October 1, compared with 216 on September 1.
• The public MDL orders checked November 10 contain no announced bellwether trial date or settlement program.

Defendants dispute the allegations. Hearing schedules do not establish an outcome, and pending-action counts do not establish settlement eligibility. State filing deadlines and settlement-program deadlines are different.

Where can I track the Ozempic / GLP-1 lawsuit?

Use the mass tort settlement tracker to compare public settlement posture, the deadline tracker for filing-window and key-date notes , and the MDL statistics tracker for federal case counts and court assignments.

What injuries does the Ozempic / GLP-1 lawsuit involve?

• Gastroparesis (delayed gastric emptying / stomach paralysis)
• Ileus and intestinal pseudo-obstruction
• Bowel obstruction
• Severe, persistent vomiting with complications
• NAION vision loss (separate proceeding — MDL-3163)

What evidence is needed for Ozempic / GLP-1 claims?

• Prescription and pharmacy records
• Records showing dates and duration of GLP-1 use
• Gastroenterology diagnosis records
• Gastric emptying study results
• Hospitalization and emergency records
• Endoscopy or imaging reports
• Treatment and medication-change records

How has the Ozempic / GLP-1 lawsuit progressed?

What is the Ozempic / GLP-1 settlement status?

The Eastern District of Pennsylvania public MDL orders reviewed November 10, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The Rule 702 proceeding concerns expert evidence, not settlement eligibility or an individual award.

What are the Ozempic / GLP-1 lawsuit filing deadlines?

Deadlines vary by state and may depend on diagnosis date, discovery date, exposure history, wrongful death issues, and other facts. A lawyer can evaluate how the relevant deadline rules may apply.

State-by-state guide links